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Abstract
Allergic asthma is characterized by airway eosinophilia, increased mucin production and allergen-specific IgE. Fc gamma
receptor IIb (FccRIIb), an inhibitory IgG receptor, has recently emerged as a negative regulator of allergic diseases like
anaphylaxis and allergic rhinitis. However, no studies to date have evaluated its role in allergic asthma. Our main objective
was to study the role of FccRIIb in allergic lung inflammation. We used a murine model of allergic airway inflammation.
Inflammation was quantified by BAL inflammatory cells and airway mucin production. FccRIIb expression was measured by
qPCR and flow cytometry and the cytokines were quantified by ELISA. Compared to wild type animals, FccRIIb deficient
mice mount a vigorous allergic lung inflammation characterized by increased bronchoalveolar lavage fluid cellularity,
eosinophilia and mucin content upon ragweed extract (RWE) challenge. RWE challenge in sensitized mice upregulated
FccRIIb in the lungs. Disruption of IFN-c gene abrogated this upregulation. Treatment of naı ¨ve mice with the Th1-inducing
agent CpG DNA increased FccRIIb expression in the lungs. Furthermore, treatment of sensitized mice with CpG DNA prior to
RWE challenge induced greater upregulation of FccRIIb than RWE challenge alone. These observations indicated that RWE
challenge upregulated FccRIIb in the lungs by IFN-c- and Th1-dependent mechanisms. RWE challenge upregulated FccRIIb
on pulmonary CD14+/MHC II+ mononuclear cells and CD11c+ cells. FccRIIb deficient mice also exhibited an exaggerated
RWE-specific IgE response upon sensitization when compared to wild type mice. We propose that FccRIIb physiologically
regulates allergic airway inflammation by two mechanisms: 1) allergen challenge mediates upregulation of FccRIIb on
pulmonary CD14+/MHC II+ mononuclear cells and CD11c+ cells by an IFN-c dependent mechanism; and 2) by attenuating
the allergen specific IgE response during sensitization. Thus, stimulating FccRIIb may be a therapeutic strategy in allergic
airway disorders.
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Introduction
Allergic asthma is an airway inflammatory disease that is
characterized by bronchial hyper-responsiveness, airway eosino-
philia, goblet cell hyperplasia and production of allergen specific
IgE. Cross-linking of the high affinity IgE receptor (FceRI) on mast
cells by IgE, in the presence of allergen activates Btk, PLC-gamma
and PI3K [1–4]. This ultimately leads to production and release of
pro-inflammatory substances like histamine, leukotrienes and
cytokines that promote allergic inflammation. In addition,
cytokines produced by allergen specific Th2 cells such as IL4,
IL5, IL9, IL13 and IL25 also promote allergen-specific IgE
production and allergic airway inflammation [5–14].
There is considerable amount of data on pro-inflammatory
mediators that contribute to the development of allergic
inflammation. However, relatively little is known about negative
regulatory mechanisms that attenuate allergic inflammation.
FccRIIb is an inhibitory low affinity IgG receptor expressed on
many inflammatory cells, including monocytes, macrophages,
dendritic cells, B cells, mast cells and basophils[15]. It negatively
regulates innate and adaptive immune responses, and has been
shown to inhibit activation of mast cells, basophils, B cells and T
cells [16–19]. It is composed of two Ig-like extra-cellular domains
that bind the Fc region of IgG, one trans-membrane domain and
an intra-cytoplasmic tail with an immuno-receptor phospho-
tyrosine based inhibitory (ITIM) motif [15,20]. Activation of
FccRIIb leads to recruitment of phosphatases to the ITIM motif
that inhibits signal transduction from other activating recep-
tors[21]. This block in the signaling cascade is the main reason for
its potent inhibitory effects on BCR-mediated B-cell activation,
TCR-mediated T-cell activation and FceRI-mediated mast cell
activation [17,22–24]. This inhibitory role is evident from studies
of FccRIIb deficient mice that are more susceptible to auto-
immune diseases and IgE mediated anaphylaxis [25–32]. Only a
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models of allergic diseases. One study showed that IgG antibodies
can prevent IgE mediated anaphylaxis in vivo through both antigen
interception and FccRIIb cross-linking [33]. Another study
demonstrated a regulatory role of FccRIIb in a murine model of
allergic rhinitis[34]. However, the role of this receptor in allergic
lung inflammation has not been elucidated.
We recently showed in a gene micro-array analysis (GEO
accession number GSE18083) that allergen challenge upregulated
352 genes in the lungs four hours after the challenge [35]. Careful
review of that list revealed FccRIIb as one of the genes
upregulated. Based on this observation, we hypothesized that
FccRIIb may play a regulatory role in allergic airway inflamma-
tion. Here we show that mice lacking FccRIIb have exaggerated
allergic airway inflammation, suggesting its negative regulatory
role in asthma. We further show that allergen challenge
upregulates FccRIIb in the lungs in an IFN-c dependent
mechanism. Our results indicate that FccRIIb upregulation
physiologically reduces allergic airway inflammation.
Materials and Methods
Ethics Statement
All animal experiments were approved by the Institutional
Animal Care and Use Committee of the University of Texas
Medical Branch at Galveston.
Mice
Female BALB/c mice, 6–8 wk old, were purchased from the
Harlan Laboratories (Indianapolis, IN). BALB/c IFN-c KO,
C57Bl6 FccRIIb knock-out (KO) and C57Bl6 WT mice were
purchased from Jackson laboratories (Bar Harbor, Maine). BALB/
cF c cRIIb knock-out (KO) mice were purchased from Taconics
(Albany, NY). All mice were maintained in a specific pathogen-
free environment throughout the experiment.
Model of Allergic Sensitization and Challenge
WT Balb/c, IFN-c KO or FccRIIb KO mice were sensitized by
two intraperitoneal (i.p.) injections of endotoxin-free RWE
(150 mg) and alum on days 0 and 4. On day 11, allergen challenge
was performed by intranasal (i.n.) instillation of RWE (200 mg) in
anesthetized mice. Mice were sacrificed at various time points as
indicated after the challenge and bronchoalveolar lavage (BAL)
fluid, blood, lung and spleen specimens were collected. Mice
sensitized but not challenged served as the zero time point. For the
Th1/CpG experiments, 35 mg CpG or GpC oligonucleotides were
administered intranasally in 50 ml of sterile PBS [36].
Ragweed Extract
We have previously shown that endotoxin contamination alters
the inflammatory cell recruitment following allergen challenge
[37]. To avoid this problem endotoxin-free ragweed (lot XP56-
D10-1320) was purchased from Greer Laboratories (Lenoir, NC).
Measurement of Allergic Airway Inflammation
For BAL fluid analyses, mice were anesthetized with an i.p.
injection of ketamine and xylazine, tracheotomy performed and
the trachea was cannulated. BAL of both lungs was performed
twice with 0.7 ml of sterile PBS (pH 7.3) through the tracheal
cannula with a syringe. Total cell counts were performed on BAL
samples and differential cell counts were done on cytocentrifuge
preparations (Cytospin 3; Thermo Shandon) stained with Wright-
Giemsa, counting 200 cells from each animal. Mucin was
quantified using mucin-binding lectin Jacalin (Calbiochem, La
jolla, CA) as described previously [38]. Aliquots of BAL fluid were
diluted 1:100, 1:1000 and 1:10000, added in triplicate to
individual wells of microtiter ELISA plates and incubated for
2 h at room temperature. Plates were washed and blocked with
5% BSA and 0.02% biotinylated jacalin was added. After 1 h
incubation at room temperature, plates were washed extensively,
then developed with alkaline phosphatase-conjugated avidin
(Sigma) and nitrophenylphosphate (Sigma) and quantified by
comparison with a mucin (Sigma) standard curve. The morpho-
metric method we described previously was used to quantify
mucin in lung epithelium[39]. Briefly, coronal sections of the 4%
paraformaldehyde-fixed lungs were stained with PAS stain.
Morphometirc analysis was done using Metamorph
TM software
(Version 5, Universal Imaging, Downingtown, Pennsylvania).
Several images from five different levels per lung (three animals
per group) were obtained and reassembled using the montage
stage stitching algorithm of the Metamorph
TM software. The
integrated morphometric analysis function was used to transform
total pixel area of the signal to mm
2 per mm of peribronchial
diameter.
Measurement of Enhanced Pause Index (PENH Index)
PENH was assessed by a method previously described [40]
using a dual chamber whole body plethysmograph obtained from
Buxco (Troy, NY). Mice were exposed for 3 min to nebulized PBS
and subsequently to 37.5 mg/ml nebulized methacholine (Sigma
Chemicals) in PBS using the AeroSonic ultrasonic nebulizer. After
each nebulization, recordings were taken for 4 min. The PENH
values measured during each 4 min sequence were averaged and
expressed as the percentage of baseline PENH values after PBS
exposure.
Quantification of Serum RWE-Specific IgE
Serum was collected from RWE-sensitized WT and FccRIIb
KO mice 4 h after challenge with PBS (WT PBS and KO PBS) or
RWE (WT RWE and KO RWE). RWE-specific IgE was
quantified using standard sandwich ELISA technique and
comparison with an IgE standard curve as described previous-
ly[41].
Antigen Recall Assay
Splenocytes were obtained from sensitized WT and FccRIIb
KO mice after crushing the spleens and making single cell
suspensions. These were incubated with or without RWE for 3 d
and Th2 cytokines (IL-4, IL-5, IL-9 and IL-13) were quantified in
the supernatants using standard ELISA techniques as described
previously [36,41,42].
Quantitative RT-PCR
Balb/c mice sensitized with RWE were challenged with either
RWE or PBS. Mice were sacrificed and lungs collected at 1, 4, 24,
72 and 240 h post-challenge. RNA was extracted and quantitative
PCR analyses were performed using the SYBR green real time
PCR kit (Applied Biosystems) as described previously [35,43].
Transcript copy numbers for FccRIIb and beta-actin were
quantified by comparing to a standard curve generated from
serial log-dilutions of the target DNA [44,45]. FccRIIb signal was
normalized to beta-actin. Table 1 shows the primers used.
Flow Cytometry
Single cell suspensions of lung and spleen were analyzed by flow
cytometry [46]. Cells were washed 3X with PBS and resuspended
in FACS staining media containing 0.5% FBS in PBS. To study
FccRIIb Inhibits Asthma
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6 cells were
incubated with anti-CD11c PE (Pharmingen, Clone HL3) and
anti-CD16/CD32-biotin (Pharmingen, Clone 2.4G2) for 30 min
on ice protected from light. After three washes, cells were
incubated with Streptavidin Cy-chrome (Pharmingen, #554062).
Species and isotype matched antibodies were used as controls.
FACS analysis was performed using analytical Flow cytometer
(FACS Scan, Beckton Dickinson) with CellQuest software (San
jose, CA). Further analyses were performed using FlowJo software
(Tree Star Inc., Ashland, OR). Similarly, FccRIIb expression on
macrophages (anti-CD14; Clone rmC5-3, Pharmingen and anti-
MHC class II-FITC; Miltenyi biotech, #130-081-601) and B cells
(anti-B220, Clone RA3-6B2, Pharmingen) was studied.
Statistical Methods
There were 4–6 animals in each group and results are
representative of at least two independent experiments. Statistical
significance between groups was determined using Student’s T
test.
Results
Disruption of the FccRIIb Gene Augments Allergic Airway
Inflammation
We assessed the biological role of FccRIIb in a murine model of
allergic asthma. C57Bl6 wild type (WT) and C57Bl6 FccRIIb
knock-out (KO) mice were sensitized and then challenged with
RWE. RWE challenge in WT mice recruited 3-fold more total
inflammatory cells, 10-fold more eosinophils, 2-fold more
lymphocytes and macrophages (Figure 1A, 1B, 1C and 1D).
Disrupting the FccRIIb gene further increased total inflammatory
cells (5-fold), eosinophils (12-fold), lymphocytes (5-fold) and
macrophages (3.6-fold) in the BAL (Figure 1A, 1B, 1C and
1D). To determine the reproducibility of this result in a different
strain of mouse, we repeated this experiment in Balb/c mice.
RWE challenge in WT Balb/c mice recruited 3-fold more total
inflammatory cells, 32-fold more eosinophils and 3-fold more
lymphocytes in BAL as compared to PBS challenge (Figure 2A,
2B and 2C) at 72 h post-challenge. Similar to our observations in
C57Bl6 mice, RWE challenge in Balb/c FccRIIb KO mice
further increased total cells (2.3-fold increase), eosinophils (5.2-fold
increase) and lymphocytes (2-fold increase) in BAL fluid as
compared to WT mice (Figure 2A, 2B and 2C). RWE challenge
in WT mice increased mucin-containing cells in the airway
(Figures 2D, 2E and 2G) and mucin levels in BAL fluid
(Figure 2H). RWE challenge in mice that lacked FccRIIb further
increased mucin-containing cells in the airway (Figures 2E, 2F
and 2G) and mucin levels in BAL fluid (Figure 2H) as compared
to WT mice. RWE challenge in mice that lacked FccRIIb induced
greater increase in enhanced pause (PENH) index as compared to
wild type mice (Figure 2I).
RWE Challenge Upregulates FccRIIb in the Lungs by an
IFN-c-Dependent Mechanism
Since allergen challenge recruits inflammatory cells that express
FccRIIb to the lungs, and lack of FccRIIb further increases this
inflammation, we hypothesized that allergen challenge upregulates
FccRIIb on pulmonary inflammatory cells. Quantitative PCR of
lung mRNA confirmed that RWE challenge upregulated FccRIIb
as early as 4 hours post-RWE challenge, and gene expression
peaked at 24 h (Figure 3A). This upregulation was sustained till
10 d after challenge (Figure 3A). Prior studies have shown
that IFN-c and Th1 response can inhibit allergic inflammation
[39,47–50]. Since our studies suggested that FccRIIb inhibited
allergic airway inflammation, we sought to determine whether
its upregulation was Th1 or IFN-c dependent. RWE challenge
upregulated FccRIIb in wild type mice but not in IFN-c KO mice
(Figure 3B). IFN-c KO mice also exhibited greater allergic
Table 1. Primers used for quantitative PCR analyses.
Gene Forwad Primer Reverse Primer
b-actin ACACCTTCTACAATGAGCTG GGATCTTCATGAGGTAGTCC
FccRIIb ATCTTGCTGCTGGGACTCAT TGACTGTGGCCTTAAACGTG
doi:10.1371/journal.pone.0009337.t001
Figure 1. Role of FccRIIb in allergic airway inflammation. (A, B, C and D) Total inflammatory cells (A), eosinophils (B), macrophages (C) and
lymphocytes (D) were quantified in BAL of C57Bl6 RWE-sensitized WT and FccRIIb KO mice challenged with either PBS (WT PBS and KO PBS) or RWE
(WT RWE and KO RWE). *, p,0.05.
doi:10.1371/journal.pone.0009337.g001
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Treatment of naı ¨ve wild type mice with the Th1-inducing CpG
DNA significantly upregulated FccRIIb; however, GpC control
DNA (which does not induce IFN-c) failed to do so (Figure 3C).
Furthermore, intra-nasal administration of CpG DNA, but not
GpC DNA, 48 h prior to RWE challenge in wild type mice
enhanced RWE-induced FccRIIb upregulation (Figure 3D).
These findings indicated that RWE-challenge upregulated FccRIIb
by an IFN-c and Th1-dependent mechanism.
RWE Challenge Upregulates FccRIIb in CD14+ MHC
II+ Mononuclear Cells and CD11c+ Cells in the Lungs
We verified the upregulation of FccRIIb in the lungs by
flow cytometry measurements of single cell suspensions of whole
lungs. RWE challenge upregulated FccRIIb on pulmonary
CD14+/MHC II+ cells (Figure 4A) and on CD11c+ cells
(Figure 4B), but not on B220+ cells (Figure 4C). Further-
more, intrapulmonary RWE challenge failed to upregulate
FccRIIb expression on these cells in the spleen (Figures 4D,
4E and 4F). This suggested that RWE challenge upregulated
FccRIIb expression on CD14+/MHC II+ and CD11c+ cells
in the challenged organ (lungs) with no detectable systemic
upregulation.
Disruption of the FccRIIb Gene Augments Serum
RWE-Specific IgE Levels after Antigen Sensitization,
but Does Not Affect Th2 Cytokine Production in
Antigen Recall Assay
Building on the observation that FccRIIb regulated RWE
challenge induced allergic lung inflammation, we examined its role
in the sensitization process and antigen-driven Th2 cytokine
production. As shown in Figure 5A, sensitized FccRIIb KO mice
had significantly higher RWE-specific IgE levels when compared
to WT mice. We hypothesized that this enhanced IgE response in
FccRIIb KO mice was due to an exaggerated Th2 response. To
test this hypothesis we performed an antigen recall assay using
splenocytes from sensitized WT and FccRIIb KO mice.
Importantly, IL-4, IL-5 and IL-13 production in response to
RWE was similar in WT and FccRIIb KO mice (Figures 5B, 5C
and 5D). Thus, disruption of FccRIIb increased antigen-specific
Figure 2. Role of FccRIIb in allergic airway inflammation. (A, B and C) Total inflammatory cells (A), eosinophils (B) and lymphocytes (C) were
quantified in BAL of Balb/c RWE-sensitized WT and FccRIIb KO mice challenged with either PBS (WT PBS) or RWE (WT RWE and KO RWE). (D, E and F)
Lung sections were obtained from RWE-sensitized WT and FccRIIb KO mice challenged with either PBS (WT PBS) or RWE (WT RWE & KO RWE). These
sections were stained with PAS to identify mucin containing cells. (G) Mucin containing cells in the lung sections were analyzed by morphometric
analyses of PAS staining area. (H) Mucin was quantified in BAL samples by ELISA using biotinylated mucin binding lectin. (I) WT and FccRIIb KO mice
were sensitized with RWE and challenged with either PBS (WT PBS) or RWE (WT & KO RWE). PENH was measured by Buxco whole body
plethysmography. *, p,0.05.
doi:10.1371/journal.pone.0009337.g002
FccRIIb Inhibits Asthma
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production.
Discussion
FccRIIb is an inhibitory IgG receptor that can prevent BCR-,
TCR- and FceRI-mediated activation of B-, T- and mast cells by
recruitment of SHIP to its ITIM motif [17,51–54]. Multiple
studies have looked at the role of FccRIIb in down regulating
specific allergic inflammatory cells in vitro. However, only a few
studies have demonstrated its regulatory role in animal models of
allergic disease. One study showed that disruption of FccRIIb
increased nasal eosinophilia in mice sensitized and challenged with
Schistosoma egg antigen (SEA)[34]. Another study suggested a
role of upregulated FccRIIb in the inhibition of anaphylaxis[55].
In this study we demonstrated the role of FccRIIb in regulating
allergen-induced eosinophilic inflammation in the lungs. We
further showed for the first time that allergen challenge
upregulated FccRIIb in the lungs.
The genes that regulate FccRIIb expression in the lungs have
not been described. Here we demonstrate that IFNc plays a
critical role in mediating allergen-induced FccRIIb upregulation.
We recently showed that IFNc plays an important role in
upregulating Th1-associated genes such as p47 and p65 GTPases,
Socs1, Cxcl9 and Cxcl10 after allergen challenge [35]. Our
observations in the current manuscript indicate that FccRIIb is
another allergen-induced IFNc-dependent, CpG DNA inducible
gene. Other reports have demonstrated upregulation of FccRIIb
on naı ¨ve human blood-derived monocytes and dendritic cells by
IL-4[56,57]. This apparent disparity between mice and humans in
regulation of FccRIIb by Th1 and Th2 cytokines could be due to
tissue-specific differences in the regulation of FccRIIb, or may
reflect divergence in regulation of the gene in the two species.
RWE challenge upregulated FccRIIb on pulmonary CD14+/
MHC II+ macrophages in this study. Alveolar macrophages have
been shown to play a regulatory role in airway inflammation.
Monocytes/macrophages account for a large number of cells in
the airway in quiescent asthma. Removal of macrophages from the
airways of patients with asthma by BAL enhances eosinophilic
inflammation[58]. There could be several mechanisms by which
alveolar macrophages contribute to this regulatory function.
Macrophages express functional FceRI and cross-linking leads to
activation and secretion of pro-inflammatory cytokines[59,60]. It
is possible that the balance of expression of FccRIIb and FceRI by
alveolar macrophages determines a pro-inflammatory versus anti-
inflammatory role of these cells. In the present study, RWE
challenge also upregulated CXCL9 and CXCL10 (data not
shown), which are Th1-associated chemokines that have been
shown to inhibit allergic airway inflammation[61,62]. It is possible
that airway monocytes secrete these anti-inflammatory cytokines
upon FccRIIb ligation, and mediate attenuation of allergic
inflammation. Another possibility is that RWE challenge induces
the anti-inflammatory PGE2 by macrophages in an FccRIIb
dependent fashion[63].
Figure 3. Expression of FccRIIb in the lungs after RWE challenge. (A) Balb/c mice sensitized with RWE and challenged with either RWE (filled
squares) or PBS (open diamond). Mice were sacrificed 1, 4, 24, 72 and 240 h after challenge, lungs were collected and RNA was extracted. Quantitative
PCR (qPCR) analysis for FccRIIb was performed on these RNA samples using SYBR green Real time PCR kit (Applied biosystems). (B) Wild-type and INF-
c deficient BALB/c mice were sensitized with RWE, and challenged with PBS or RWE. 4 h later, the lungs were collected and qPCR for FccRIIb was
performed. (C) Naı ¨ve wild-type mice were challenged with PBS, CpG DNA or GpC DNA. 4 hours post-challenge lungs were collected and FccRIIb
expression was quantified by qPCR. (D) Wild-type BALB/c mice were sensitized with RWE. The mice were pre-treated with PBS (PBS challenge or RWE
challenge group) or 35 mg CpG oligonucleotide intranasally (CpG R RWE) 48 h prior to RWE challenge. 4 h post-challenge, lungs were collected and
qPCR for FccRIIb was performed. *=p,0.05.
doi:10.1371/journal.pone.0009337.g003
FccRIIb Inhibits Asthma
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CD11c+ cells, most likely dendritic cells. Myeloid dendritic cells
have been shown to regulate allergic airway inflammation by
inducing a Th2 immune response[64,65]. FccRIIb on DCs can
potentially inhibit the induction of the Th2 cytokine response.
However in the present study, the antigen recall assay failed to
Figure 4. Identification of cells in the lungs that upregulate FccRIIb after RWE challenge. Single cell lung and spleen suspensions were
prepared from RWE-sensitized BALB/c mice that were challenged with PBS or RWE. A multi-color FACS analysis for FccRIIb and cell specific markers
(CD14/MHC II for macrophages, CD11c for dendritic cells and B220 for B cells) was performed on these cells. FccRIIb expression is shown for PBS
challenged (grey histogram) and RWE challenged (black histogram) mice. FccRIIb expression is increased on CD14+/MHC II+ and CD11c+ gated cells.
Data from one representative animal in each group. MFI, Mean fluorescence intensity.
doi:10.1371/journal.pone.0009337.g004
Figure 5. Role of FccRIIb on serum IgE levels and antigen-induced Th2 cytokine production. (A) RWE-specific IgE levels in serum were
quantified in sensitized WT and FccRIIb KO mice. (B, C and D) Splenocytes from sensitized wild-type and FccRIIb KO mice were cultured with PBS or
RWE for four days, and the cell supernatants were analyzed for IL-4, IL-5 and IL-13 levels by ELISA. *, P,0.05; NS, not significant.
doi:10.1371/journal.pone.0009337.g005
FccRIIb Inhibits Asthma
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knockout mice. These observations suggested that FccRIIb does
not affect the antigen presenting and Th2 skewing properties of
DCs.
A previous study showed a critical role of Fc receptor gamma
chain in the sensitization phase of allergic airway inflammation
[66]. In the present study, absence of FccRIIb increased levels of
allergen specific IgE after sensitization. This indicated that
FccRIIb can specifically attenuate IgE humoral responses,
suggesting its specific regulatory role in allergic lung inflammation.
IgE production by the differentiating B cell requires class switch
recombination (CSR) to Ce that is CD40 and IL-4 depen-
dent[67,68]. FccRIIb deficient splenocytes made similar amount
of IL-4 as wild type splenocytes in allergen recall assay. Thus, T
cell-secreted IL-4 might not be involved in the FccRIIb-mediated
suppression of Ce class switch. One possibility is that FccRIIb
suppresses CD40L expression on T cells thus reducing the stimulus
for IgE class switch. Another mechanism might involve regulation
of IgE production by DCs. CSR in B cells is regulated by the
expression of BAFF (BLyS) and APRIL on DCs[69–71]. One
report showed inhibition of B cell IgE production by DCs via
direct cell-cell interaction as well as by soluble factors including
TGF-b and IFN-c[72]. It is possible that FccRIIb expression
affects the ability of DCs to regulate IgE production by B cells. Yet
another possibility is that the enhanced IgE response in FccRIIb
deficient mice is independent of the Th2 T cell response.
Upregulation of FccRIIb on mast cells after exposure to
allergen can lead to co-ligation of FccRIIb and FceRI by allergen
and inhibit activation/degranulation of the mast cell. This concept
was exploited in recent studies using two novel bio-engineered
fusion proteins, one that consists of human Fc regions of IgG1 and
IgE linked together and another a fusion protein made by linking
an allergen to human IgG1 Fc region[73]. These proteins block
pro-inflammatory mediator and cytokine release from allergic cells
and prevent skin, lung and systemic allergic reactivity in a murine
model[16,73–77]. Our study demonstrates that FccRIIb-depen-
dent regulatory mechanism(s) control allergic airway inflamma-
tion, making this inhibitory receptor a physiologically relevant
therapeutic target in allergic asthma. FccRIIb appears to inhibit
both allergic sensitization (possibly by attenuating the IgE
response) as well as allergic inflammation from allergen exposure
(possibly by upregulating FccRIIb expression on inflammatory
cells in the target organ). Stimulating the inhibitory FccRIIb
receptor is an elegant strategy because it is naturally upregulated
by allergen exposure, and has the potential of controlling allergic
inflammation by inhibiting multiple cells and mediators. In this
manner it is likely to alter airway remodeling and disease
progression.
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